RATIONALE: Exceedingly little experimental research exists on the popular recreational drug mephedrone (4-methylmethcathinone) despite clinical reports concerning its behavioral and cardiovascular toxicity. OBJECTIVES: To characterize mephedrone preclinically by examining its capacity to (1) serve as a discriminative stimulus, (2) disrupt the acquisition of response sequences, and (3) disrupt mean arterial pressure (MAP) and heart rate (HR). METHODS AND RESULTS: In one group of subjects that reliably discriminated 3.2 mg/kg of mephedrone from saline (n = 9), substitution tests indicated that stimulants (cocaine, MDMA, and methamphetamine) more closely approximated the mephedrone discriminative stimulus than non-stimulants (fenfluramine, morphine, and phencyclidine), although none fully substituted. In a second group (n = 6), mephedrone (0.56-10 mg/kg, i.p.) dose-dependently decreased response rate and increased errors in both components of a procedure in which subjects either acquired a new response sequence each session (repeated acquisition) or completed the same response sequence each session (performance). Finally, in a third group (n = 12), radio telemetry probes were used to measure the changes in MAP and HR elicited by mephedrone and then compared them to a known stimulant, methamphetamine. In these studies, mephedrone (0.01-9 mg/kg, i.v.) elicited increases in MAP and HR that were very similar to those elicited by methamphetamine (0.01-9 mg/kg, i.v.). The tachycardia and pressor responses to mephedrone (3 mg/kg) were blocked by the β-blocker atenolol (1 mg/kg, i.v.) and the α1, α2-blocker phentolamine (3 mg/kg, i.v.), respectively. CONCLUSIONS: Mephedrone produces behavioral and cardiovascular responses that are similar to other stimulants; however, differences from the classical stimulants were also apparent.
RATIONALE: Exceedingly little experimental research exists on the popular recreational drug mephedrone (4-methylmethcathinone) despite clinical reports concerning its behavioral and cardiovascular toxicity. OBJECTIVES: To characterize mephedrone preclinically by examining its capacity to (1) serve as a discriminative stimulus, (2) disrupt the acquisition of response sequences, and (3) disrupt mean arterial pressure (MAP) and heart rate (HR). METHODS AND RESULTS: In one group of subjects that reliably discriminated 3.2 mg/kg of mephedrone from saline (n = 9), substitution tests indicated that stimulants (cocaine, MDMA, and methamphetamine) more closely approximated the mephedrone discriminative stimulus than non-stimulants (fenfluramine, morphine, and phencyclidine), although none fully substituted. In a second group (n = 6), mephedrone (0.56-10 mg/kg, i.p.) dose-dependently decreased response rate and increased errors in both components of a procedure in which subjects either acquired a new response sequence each session (repeated acquisition) or completed the same response sequence each session (performance). Finally, in a third group (n = 12), radio telemetry probes were used to measure the changes in MAP and HR elicited by mephedrone and then compared them to a known stimulant, methamphetamine. In these studies, mephedrone (0.01-9 mg/kg, i.v.) elicited increases in MAP and HR that were very similar to those elicited by methamphetamine (0.01-9 mg/kg, i.v.). The tachycardia and pressor responses to mephedrone (3 mg/kg) were blocked by the β-blocker atenolol (1 mg/kg, i.v.) and the α1, α2-blocker phentolamine (3 mg/kg, i.v.), respectively. CONCLUSIONS:Mephedrone produces behavioral and cardiovascular responses that are similar to other stimulants; however, differences from the classical stimulants were also apparent.
Authors: David M Wood; Susannah Davies; Malgorzata Puchnarewicz; Jenny Button; Roland Archer; Hanna Ovaska; John Ramsey; Terry Lee; David W Holt; Paul I Dargan Journal: J Med Toxicol Date: 2010-09
Authors: Peter J Winsauer; Jill M Daniel; Catalin M Filipeanu; Stuart T Leonard; Jerielle L Hulst; Shaefali P Rodgers; Caroline L Lassen-Greene; Jessie L Sutton Journal: Addict Biol Date: 2011-01 Impact factor: 4.280
Authors: Adam Winstock; Luke Mitcheson; John Ramsey; Susannah Davies; Malgorzata Puchnarewicz; John Marsden Journal: Addiction Date: 2011-07-27 Impact factor: 6.526
Authors: Kevin C Lord; Sylvia K Shenouda; Elizabeth McIlwain; Dimitrios Charalampidis; Pamela A Lucchesi; Kurt J Varner Journal: Cardiovasc Res Date: 2010-02-05 Impact factor: 10.787
Authors: Jennifer E Naylor; Kevin B Freeman; Bruce E Blough; William L Woolverton; Sally L Huskinson Journal: Drug Alcohol Depend Date: 2015-02-11 Impact factor: 4.492
Authors: Charles W Schindler; Eric B Thorndike; Kenner C Rice; John S Partilla; Michael H Baumann Journal: J Pharmacol Exp Ther Date: 2019-03-21 Impact factor: 4.030
Authors: William E Fantegrossi; Brenda M Gannon; Sarah M Zimmerman; Kenner C Rice Journal: Neuropsychopharmacology Date: 2012-11-08 Impact factor: 7.853